Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Cerebrospinal fluid (CSF) biomarker analysis for dementia diagnostics (ie, the analysis of amyloid β42, total tau and phosphorylated tau) is increasingly used in clinical practice.1 However, there is still debate among researchers and clinicians about the sensitivity and specificity of various biomarker analyses, especially when comparing dementia subtypes.2 The lack of consensus and heterogeneity for evidence on CSF biomarker use and validity is likely to have resulted in variable practices: belief in the utility of biomarker measurement has likely stimulated the use of CSF analysis in clinical practice in some places whereas elsewhere this practice probably has not been adopted at all. The extent of this variability …
Competing interests None.
Provenance and Peer review Not commissioned; externally peer reviewed.